Medpace stock is up 69% since my original buy rating, backed by strong profitability and cash flow generation.Q2 earnings show continued growth and backlog strength, with potential for further value ...
Source LinkMedpace stock is up 69% since my original buy rating, backed by strong profitability and cash flow generation.Q2 earnings show continued growth and backlog strength, with potential for further value ...
Source Link
Comments